MONCTON, NB, June 29, 2018 /CNW/ - Organigram Holdings Inc.
(TSX VENTURE: OGI) (OTCQB: OGRMF), the parent company of Organigram
Inc. (the "Company" or "Organigram"), a leading licensed producer
of medical marijuana based in Moncton,
New Brunswick, is pleased to announce that it has been
approved as a supplier of cannabis for the province of Manitoba.
"We are proud to work with MBLL to offer residents of
Manitoba a choice of high-quality
cannabis products," says Tim Emberg,
Organigram Vice President of Sales and Commercial Operations. "As
we expand our own national footprint, we look forward to working
with retailers in Manitoba to
deliver an exceptional customer experience."
Organigram continues to expand its national presence
The agreement with MBLL represents another milestone in the
Company's strategic plan to work with regulators and distributors
across the country.
Organigram has signed two previous memorandums of understanding
including an MOU with the Government of New Brunswick (GNB), signed in 2017 to supply
a minimum of 5-million grams of cannabis a year worth an estimated
retail value of between $40-million
to $60-million per year.
In 2018, the Company also signed an MOU with the Prince Edward
Island Liquor Control Commission for the distribution of cannabis
to the province's adult recreational market. That agreement is
estimated to have a retail value of between $8-million to $12-million per year.
"We are pleased to continue to build – and formalize – positive,
productive working relationships with partners across the country
and help ensure the success of new adult-use recreational cannabis
markets in each of these regions," says Greg Engel, Organigram CEO.
For more information, visit www.Organigram.ca
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed
company whose wholly owned subsidiary, Organigram Inc., is a
licensed producer of medical marijuana in Canada. Organigram is focused on producing the
highest-quality, condition-specific medical marijuana for patients
in Canada. Organigram's facility
is located in Moncton, New
Brunswick and the Company is regulated by the Access to
Cannabis for Medical Purposes Regulations ("ACMPR").
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectations. Important factors - including the availability of
funds, consummation of definitive documentation, the results of
financing efforts, crop yields - that could cause actual results to
differ materially from the Company's expectations are disclosed in
the Company's documents filed from time to time on SEDAR (see
www.sedar.com). Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE OrganiGram